NSD3 - New-wiki

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	AP3M2	adaptor related protein complex 3 subunit mu 2
Novel	BMP8B	bone morphogenetic protein 8b
Novel	E2F5	E2F transcription factor 5	Transcription of E2F targets under negative control by DREAM complex Transcription of E2F targets under negative control by DREAM complex Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Cyclin E associated events during G1/S transition G1/S-Specific Transcription G1/S-Specific Transcription Cyclin D associated events in G1 Cyclin A:Cdk2-associated events at S phase entry
Novel	ETV6	ETS variant transcription factor 6	Signaling by membrane-tethered fusions of PDGFRA or PDGFRB Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins		Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
Novel	IVNS1ABP	influenza virus NS1A binding protein
Novel	LSM1	LSM1 homolog, mRNA degradation associated	mRNA decay by 5' to 3' exoribonuclease mRNA decay by 5' to 3' exoribonuclease
Novel	SQSTM1	sequestosome 1	NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival PINK1-PRKN Mediated Mitophagy Interleukin-1 signaling Pexophagy		Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
	AKT1	AKT serine/threonine kinase 1	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling CTLA4 inhibitory signaling G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling	ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
	ATM	ATM serine/threonine kinase	DNA Damage/Telomere Stress Induced Senescence Regulation of HSF1-mediated heat shock response Autodegradation of the E3 ubiquitin ligase COP1 HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Caspase Activators and Caspases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Meiotic recombination Pexophagy	Caffeine	Ataxia telangiectasia (AT); Louis-Bar syndrome; Boder-Sedgwick syndrome DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2) Chronic lymphocytic leukemia (CLL)
	BCAR3	BCAR3 adaptor protein, NSP family member
	CASP8	caspase 8	Apoptotic cleavage of cellular proteins Caspase activation via Death Receptors in the presence of ligand NOD1/2 Signaling Pathway TRIF-mediated programmed cell death Caspase-mediated cleavage of cytoskeletal proteins Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling CLEC7A/inflammasome pathway Regulation of necroptotic cell death Dimerization of procaspase-8 Activation, myristolyation of BID and translocation to mitochondria Apoptotic execution phase FasL/ CD95L signaling TRAIL signaling TLR3-mediated TICAM1-dependent programmed cell death NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Microbial modulation of RIPK1-mediated regulated necrosis Defective RIPK1-mediated regulated necrosis	Bryostatin 1 Bardoxolone	Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
	CBLC	Cbl proto-oncogene C
	CBX3	chromobox 3	ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression RNA Polymerase I Promoter Escape Transcriptional Regulation by E2F6
	CBX5	chromobox 5	SUMOylation of chromatin organization proteins Transcriptional Regulation by E2F6 Factors involved in megakaryocyte development and platelet production	Copper
	CDKN2A	cyclin dependent kinase inhibitor 2A	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects		Bladder cancer Type II diabetes mellitus Pancreatic cancer Burkitt lymphoma Adult T-cell leukemia Malignant pleural mesothelioma Non-small cell lung cancer Chronic myeloid leukemia (CML) Oral cancer Penile cancer Nasopharyngeal cancer Glioma Osteosarcoma Squamous cell carcinoma Cholangiocarcinoma Gallbladder cancer Malignant islet cell carcinoma Laryngeal cancer Hepatocellular carcinoma Esophageal cancer Malignant melanoma
	CHEK2	checkpoint kinase 2	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Ubiquitin Mediated Degradation of Phosphorylated Cdc25A Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	XL844 Enzastaurin Fostamatinib	Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
	DAXX	death domain associated protein	SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
	DOCK7	dedicator of cytokinesis 7	MET activates RAP1 and RAC1 Factors involved in megakaryocyte development and platelet production
	ESR1	estrogen receptor 1	Nuclear signaling by ERBB4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors RUNX1 regulates estrogen receptor mediated transcription ESR-mediated signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Extra-nuclear estrogen signaling Estrogen-dependent gene expression	Diethylstilbestrol Chlorotrianisene Conjugated estrogens Desogestrel Levonorgestrel Progesterone Lindane Raloxifene Toremifene Medroxyprogesterone acetate Testosterone Mitotane Estrone Tamoxifen Hexachlorophene Estradiol Ethynodiol diacetate Dobutamine Clomifene Dienestrol Fulvestrant Norgestimate Ethinylestradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Oxybenzone Allylestrenol Zinc Genistein Prasterone Benzophenone Equilin Compound 19 Resveratrol Compound 18 Phthalic Acid Pyrazole Stanolone Naringenin Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Quercetin Afimoxifene 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estrone sulfate Quinestrol Phenolphthalein Permethrin Ospemifene AP1081 Custirsen NP-50301 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Elacestrant Bazedoxifene Methyltestosterone beta-Naphthoflavone 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Hexestrol dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate Erteberel N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol Tibolone Eugenol Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, B Polyestradiol phosphate Norethynodrel Octocrylene Homosalate Enzacamene Zeranol Ractopamine Gestrinone Propyl Gallate 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Zinc acetate Zinc chloride Zinc sulfate, unspecified form Estriol tripropionate Fluoroestradiol F-18
	ETV3	ETS variant transcription factor 3

Search Results for: NSD3